Regulatory | Cyprotex

Archive for the ‘Regulatory’ Category

It can be challenging to navigate the requirements for drug interaction studies when each regulatory authority has […]

On 15th September 2021, the European parliament adopted a resolution vote to actively phase out the use […]

In January 2020, the US FDA gave its stamp of approval by finalising its 2017 draft regulatory […]

The most important OATP family member expressed in the human liver is OATP1B1, responsible for hepatic uptake […]

PK/PD modelling is an important aspect of dose prediction of antibiotics for both preclinical and clinical development […]

This website is intended to assist industry participants, customers and employees to understand Cyprotex's global operations and ambitions.